In this qualitative study, the authors examined the nature of resilience in people with chronic disabilities. Fifteen people with disabilities identified the factors that helped or hindered them at major turning points, and the triggers and resolutions to these turning points. Turning points were emotionally compelling experiences and realizations that involved meaning acquired through the routes of belonging, doing, or understanding the self or the world. The major protective factors were social support, traits such as perseverance and determination, and spiritual beliefs. Three new protective processes were identified: replacing a loss with a gain (transcending), recognizing new things about oneself (self-understanding), and making decisions about relinquishing something in life (accommodating). These protective factors, processes, and ways in which people with disabilities draw sense and meaning in life have important implications for service delivery.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/1049732302239598 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies.
Nat Med
January 2025
Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Long-term risks of gene therapy are not fully understood. In this study, we evaluated safety outcomes in 783 patients over more than 2,200 total patient-years of observation from 38 T cell therapy trials. The trials employed integrating gammaretroviral or lentiviral vectors to deliver engineered receptors to target HIV-1 infection or cancer.
View Article and Find Full Text PDFTurning the Tide of Viral Hepatitis-Induced Acute Liver Failure: The Role of Standard Volume Plasma Exchange in Adults and Children.
Transfus Clin Biol
January 2025
Department of Immunohematology and Blood Transfusion, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Dehradun 248140 Uttarakhand, India.
Introduction: Therapeutic plasma exchange (TPE) is the most widely used artificial liver support system in liver failure patients.
Cases: We report five cases of viral hepatitis induced ALF 3 adult (case I, II, III) and two pediatric (case IV and V) patients not adequately responding to standard medical treatment (SMT). Case I and II were acute hepatitis B infections while case III was an antenatal case with acute hepatitis E.
The Burden of Diabetes in the Southeastern Coastal Region of China From 1990 to 2019 and Projections for 2030: A Systematic Analysis of the 2019 Global Burden of Disease Study.
Diabetes Metab Res Rev
January 2025
Department for Chronic and Noncommunicable Disease Control and Prevention, Fujian Provincial Center for Disease Control and Prevention, Fuzhou, China.
Aim: This study examined the diabetes burden in Fujian Province, China, from 1990 to 2019, comparing it with China and global levels to inform policymakers.
Materials And Methods: We used data from GBD 2019 to analyse diabetes prevalence, death, and disability-adjusted life-years (DALYs). We assessed the average annual percentage change (AAPC) and estimated the impact of 17 risk factors.
Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) signaling promotes cell growth and differentiation, and is overexpressed in several tumor types, including breast, gastric and colorectal cancer. HER2-targeted therapies have shown clinical activity against these tumor types, resulting in regulatory approvals. However, the efficacy of HER2 therapies in tumors with HER2 mutations has not been widely investigated.
View Article and Find Full Text PDFPhase I study of BMS-986299, an NLRP3 agonist, as monotherapy and in combination with nivolumab and ipilimumab in patients with advanced solid tumors.
J Immunother Cancer
January 2025
Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Purpose: BMS-986299 is a first-in-class, NOD-, LRR-, and pyrin-domain containing-3 (NLRP3) inflammasome agonist enhancing adaptive immune and T-cell memory responses.
Materials And Methods: This was a phase-I (NCT03444753) study that assessed the safety and tolerability of intra-tumoral BMS-986299 monotherapy (part 1A) and in combination (part 1B) with nivolumab, and ipilimumab in advanced solid tumors. Reported here are single-center results.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!